Terms: = Sarcomas AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
240 results:
1. Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and pd-l1: a case report.
Deng S; Yang X; He L; Zhang Q; Zhao C; Meng H
J Cardiothorac Surg; 2024 Apr; 19(1):194. PubMed ID: 38594687
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
3. Visual analysis of bone malignancies immunotherapy: A bibliometric analysis from 2010 to 2023.
Shen K; Yang L; Ke S; Gao W
Medicine (Baltimore); 2024 Mar; 103(13):e37269. PubMed ID: 38552042
[TBL] [Abstract] [Full Text] [Related]
4. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
5. treatment and prognostic implications of strong pd-l1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract] [Full Text] [Related]
6. Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRAS
Lin P; Cheng W; Qi X; Zhang P; Xiong J; Li J
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338834
[TBL] [Abstract] [Full Text] [Related]
7. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract] [Full Text] [Related]
8. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
9. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial.
Cho HJ; Yun KH; Shin SJ; Lee YH; Kim SH; Baek W; Han YD; Kim SK; Ryu HJ; Lee J; Cho I; Go H; Ko J; Jung I; Jeon MK; Rha SY; Kim HS
Nat Commun; 2024 Jan; 15(1):685. PubMed ID: 38263321
[TBL] [Abstract] [Full Text] [Related]
10. Ramucirumab, Avelumab, and Paclitaxel as Second-Line treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.
Thuss-Patience P; Högner A; Goekkurt E; Stahl M; Kretzschmar A; Götze T; Stocker G; Reichardt P; Kullmann F; Pink D; Bartels P; Jarosch A; Hinke A; Schultheiß C; Paschold L; Stein A; Binder M
JAMA Netw Open; 2024 Jan; 7(1):e2352830. PubMed ID: 38261316
[TBL] [Abstract] [Full Text] [Related]
11. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments.
Zhou C; Li M; Ren Y; Miao F; Wang Y; Wu T; Gou X; Li W
World J Surg Oncol; 2024 Jan; 22(1):25. PubMed ID: 38254190
[TBL] [Abstract] [Full Text] [Related]
12. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
[TBL] [Abstract] [Full Text] [Related]
13. Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Baginska J; Nau A; Gomez Diaz I; Giobbie-Hurder A; Weirather J; Vergara J; Abrecht C; Hallisey M; Dennis J; Severgnini M; Huezo J; Marciello I; Rahma O; Manos M; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Ott PA; Buchbinder EI; Hodi FS
Cancer Immunol Immunother; 2024 Jan; 73(1):17. PubMed ID: 38236249
[TBL] [Abstract] [Full Text] [Related]
14. Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization.
Brown JM; Patel R; Smith-Fry K; Ward M; Oliver T; Jones KB
Neoplasia; 2024 Feb; 48():100956. PubMed ID: 38199172
[TBL] [Abstract] [Full Text] [Related]
15. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract] [Full Text] [Related]
16. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Rajdev L; Jackie Wang CC; Joshi H; Lensing S; Lee J; Ramos JC; Baiocchi R; Ratner L; Rubinstein PG; Ambinder R; Henry D; Streicher H; Little RF; Chiao E; Dittmer DP; Einstein MH; Cesarman E; Mitsuyasu R; Sparano JA;
Cancer; 2024 Mar; 130(6):985-994. PubMed ID: 37962072
[TBL] [Abstract] [Full Text] [Related]
17. Eicosapentaenoic acid enhances the sensitivity of osteosarcoma to cisplatin by inducing ferroptosis through the DNA-PKcs/AKT/NRF2 pathway and reducing pd-l1 expression to attenuate immune evasion.
Zhang Y; Shen G; Meng T; Lv Z; Li X; Li J; Li K
Int Immunopharmacol; 2023 Dec; 125(Pt B):111181. PubMed ID: 37951196
[TBL] [Abstract] [Full Text] [Related]
18. Novel pd-l1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy.
Taborska P; Lukac P; Stakheev D; Rajsiglova L; Kalkusova K; Strnadova K; Lacina L; Dvorankova B; Novotny J; Kolar M; Vrana M; Cechova H; Ransdorfova S; Valerianova M; Smetana K; Vannucci L; Smrz D
Sci Rep; 2023 Nov; 13(1):19079. PubMed ID: 37925511
[TBL] [Abstract] [Full Text] [Related]
19. Immune microenvironment of intimal sarcomas: Adaptive immune resistance with potential therapeutic implications.
Birkness-Gartman JE; Thomas DL; Engle LL; Voltaggio L; Thompson ED
Am J Clin Pathol; 2024 Mar; 161(3):256-263. PubMed ID: 37921094
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
[Next]
